Background/aims: We have studied the effects of insoluble glycogen applied intravenously on the experimental acute pancreatitis of dogs.
Methods: Experimental acute pancreatitis was induced by olive oil injected into the main pancreatic duct. The effects of insoluble glycogen were evaluated histologically and by measurements of levels of amylase, lipase in sera. The binding of endotoxin and secretable phospholipase A2 by insoluble glycogen were tested by isotopically labeled materials.
Results: Application of insoluble glycogen had beneficial effects on the experimental acute pancreatitis of dogs.
Conclusion: The binding capacity on endotoxin and secretable phospholipase A2 could play the main role in the protection offered by insoluble glycogen.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease.
EMBO J
January 2025
Division of Neurology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD). Brain polyglucosan bodies (PBs) cause fatal neurodegenerative diseases including Lafora disease and adult polyglucosan body disease (ABPD), for which treatments, biomarkers, and good understanding of their pathogenesis are currently missing. Mutations in the genes for the phosphatase laforin or the E3 ubiquitin ligase malin can cause LD.
View Article and Find Full Text PDFStructure and strain specificity for polysaccharides from king oyster mushroom (Pleurotus eryngii) fruiting bodies.
Int J Biol Macromol
January 2025
Department of Crop Production, Czech University of Life Sciences Prague, Czech Republic.
King oyster mushroom Pleurotus eryngii is cultivated worldwide for culinary and to improve human health. However, the potential of some Mediterranean representatives of this species is still not evaluated. This work focuses on the study of polysaccharides from fruiting bodies of two Tunisian strains, P.
View Article and Find Full Text PDFLafora disease (LD; OMIM#254780) is a rare form of progressive myoclonus epilepsy characterized by the accumulation of insoluble deposits of aberrant glycogen (polyglucosans), named Lafora bodies (LBs), in the brain but also in peripheral tissues. It is assumed that the accumulation of LBs is related to the appearance of the characteristic pathological features of the disease. In mouse models of LD, we and others have reported an increase in the levels of reactive astrocytes and activated microglia, which triggers the expression of the different pro-inflammatory mediators.
View Article and Find Full Text PDFGene therapy for Lafora disease in the Epm2a mouse model.
Mol Ther
July 2024
Laboratory of Neurology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain. Electronic address:
Lafora disease is a rare and fatal form of progressive myoclonic epilepsy typically occurring early in adolescence. The disease results from mutations in the EPM2A gene, encoding laforin, or the EPM2B gene, encoding malin. Laforin and malin work together in a complex to control glycogen synthesis and prevent the toxicity produced by misfolded proteins via the ubiquitin-proteasome system.
View Article and Find Full Text PDFImpaired malin expression and interaction with partner proteins in Lafora disease.
J Biol Chem
May 2024
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA; Lafora Epilepsy Cure Initiative, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Lafora disease (LD) is an autosomal recessive myoclonus epilepsy with onset in the teenage years leading to death within a decade of onset. LD is characterized by the overaccumulation of hyperphosphorylated, poorly branched, insoluble, glycogen-like polymers called Lafora bodies. The disease is caused by mutations in either EPM2A, encoding laforin, a dual specificity phosphatase that dephosphorylates glycogen, or EMP2B, encoding malin, an E3-ubiquitin ligase.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!